Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure

Second-line therapy for corticosteroid-refractory or -dependent acute graft-versus-host disease remains ill-defined, due to limited efficacy of drugs and evolving clinical trial endpoints. Six-month freedom from treatment failure has been proposed as a novel clinical trial endpoint and is defined by...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Das-Gupta, Emma, Greinix, Hildegard, Jacobs, Ryan, Zhou, Li, Savani, Bipin N., Engelhardt, Brian G., Kassim, Adetola, Worel, Nina, Knobler, Robert, Russell, Nigel, Jagasia, Madan
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2014
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4222474/
https://ncbi.nlm.nih.gov/pubmed/25150260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.108217
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars